<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74065</article-id><article-id pub-id-type="doi">10.7554/eLife.74065</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-254098"><name><surname>Cui</surname><given-names>Can</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8138-0495</contrib-id><email>can.cui@ki.se</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254967"><name><surname>Ingre</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254968"><name><surname>Yin</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-155399"><name><surname>Li</surname><given-names>Xia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1922-7152</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107694"><name><surname>Andersson</surname><given-names>John</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2799-6349</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254969"><name><surname>Seitz</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254970"><name><surname>Ruffin</surname><given-names>Nicolas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3698-5505</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254971"><name><surname>Pawitan</surname><given-names>Yudi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-89446"><name><surname>Piehl</surname><given-names>Fredrik</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-34317"><name><surname>Fang</surname><given-names>Fang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3310-6456</contrib-id><email>fang.fang@ki.se</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056d84691</institution-id><institution>Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet</institution></institution-wrap><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00m8d6786</institution-id><institution>SLL- ME Neurologi, Karolinska University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056d84691</institution-id><institution>Department of Clinical Neuroscience, Karolinska Institutet</institution></institution-wrap><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056d84691</institution-id><institution>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</institution></institution-wrap><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tanzi</surname><given-names>Rudolph E</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dulac</surname><given-names>Catherine</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>03</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e74065</elocation-id><history><date date-type="received" iso-8601-date="2021-09-20"><day>20</day><month>09</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-02-16"><day>16</day><month>02</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-10-07"><day>07</day><month>10</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.10.05.21264570"/></event></pub-history><permissions><copyright-statement>© 2022, Cui et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Cui et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74065-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74065-figures-v1.pdf"/><abstract><p>The prognostic role of immune cells in amyotrophic lateral sclerosis (ALS) remains undetermined. Therefore, we conducted a longitudinal cohort study including 288 ALS patients with up to 5-year follow-up during 2015–2020 recruited at the only tertiary referral center for ALS in Stockholm, Sweden, and measured the levels of differential leukocytes and lymphocyte subpopulations. The primary outcome was risk of death after diagnosis of ALS and the secondary outcomes included functional status and disease progression rate. Cox model was used to evaluate the associations between leukocytes and risk of death. Generalized estimating equation model was used to assess the correlation between leukocytes and functional status and disease progression rate. We found that leukocytes, neutrophils, and monocytes increased gradually over time since diagnosis and were negatively correlated with functional status, but not associated with risk of death or disease progression rate. For lymphocyte subpopulations, NK cells (HR= 0.61, 95% CI = [0.42–0.88] per SD increase) and Th2-diffrentiated CD4<sup>+</sup> central memory T cells (HR= 0.64, 95% CI = [0.48–0.85] per SD increase) were negatively associated with risk of death, while CD4<sup>+</sup> effector memory cells re-expressing CD45RA (EMRA) T cells (HR= 1.39, 95% CI = [1.01–1.92] per SD increase) and CD8<sup>+</sup> T cells (HR= 1.38, 95% CI = [1.03–1.86] per SD increase) were positively associated with risk of death. None of the lymphocyte subpopulations was correlated with functional status or disease progression rate. Our findings suggest a dual role of immune cells in ALS prognosis, where neutrophils and monocytes primarily reflect functional status whereas NK cells and different T lymphocyte populations act as prognostic markers for survival.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>amyotrophic lateral sclerosis</kwd><kwd>prognosis</kwd><kwd>immune cells</kwd><kwd>blood flow</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>Starting Grant</award-id><principal-award-recipient><name><surname>Fang</surname><given-names>Fang</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Swedish Research Council</institution></institution-wrap></funding-source><award-id>No. 2019-01088</award-id><principal-award-recipient><name><surname>Fang</surname><given-names>Fang</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004047</institution-id><institution>Karolinska Institutet</institution></institution-wrap></funding-source><award-id>Strategic Research Area in Epidemiology and Senior Researcher Award</award-id><principal-award-recipient><name><surname>Fang</surname><given-names>Fang</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004543</institution-id><institution>China Scholarship Council</institution></institution-wrap></funding-source><award-id>201700260293</award-id><principal-award-recipient><name><surname>Cui</surname><given-names>Can</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>MegaALS, No. 802091</award-id><principal-award-recipient><name><surname>Fang</surname><given-names>Fang</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A dual role of immune cells was found in ALS prognosis, where neutrophils and monocytes primarily reflect functional status whereas NK cells and different T lymphocyte populations act as prognostic markers for survival.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Amyotrophic lateral sclerosis (ALS) is a rare but devastating neurodegenerative disease. Although a genetic cause has been demonstrated for some cases of ALS, the etiology remains unknown for most of the patients with ALS. There is currently no cure or effective treatment available for ALS. A range of potential disease mechanisms have however been proposed, with potential for informing on novel therapeutic targets (<xref ref-type="bibr" rid="bib51">Zarei et al., 2015</xref>).</p><p>Neuroinflammatory features, including local glial activation and T-cell infiltration in the central nervous system (CNS), are well documented in ALS (<xref ref-type="bibr" rid="bib21">Komine and Yamanaka, 2015</xref>). Animal studies have demonstrated that altering the function of microglia and infiltrating T cells to the CNS affect disease progression in experimental ALS (<xref ref-type="bibr" rid="bib3">Beers et al., 2006</xref>; <xref ref-type="bibr" rid="bib29">Martínez-Muriana et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Beers et al., 2008</xref>). Human studies have also documented signs of systemic immune activation in ALS patients, compared with healthy controls, suggesting that peripheral immune activation may play a role in human ALS through the peripheral–central neuroimmune crosstalk (<xref ref-type="bibr" rid="bib24">Liu et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Jin et al., 2020</xref>). Most of the previous studies (<xref ref-type="bibr" rid="bib17">Jin et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Rentzos et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Henkel et al., 2012</xref>), however, are not population based and have limited sample size, raising the concern of potentially insufficient internal (e.g., selection bias and chance finding) and external (e.g., lack of generalizability) validity. Further, few studies have recorded immune cells longitudinally after ALS diagnosis, as most previous studies relied on a single measurement (<xref ref-type="bibr" rid="bib44">Sheean et al., 2018</xref>).</p><p>The main purpose of this study was to determine cellular immune changes occurring over time since diagnosis of ALS and their prognostic values in a large clinical sample. For this purpose, we enrolled a longitudinal cohort of ALS patients, representing a large proportion of the entire ALS population in Stockholm, Sweden, to (1) describe the temporal changes of peripheral leukocytes over time since ALS diagnosis, (2) assess the association of immune cell dynamics with the risk of death after ALS diagnosis, and (3) evaluate the correlations of different cell populations with the functional status and disease progression rate of ALS.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Leukocytes and lymphocyte subtypes in ALS</title><p><xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> shows the distribution of leukocyte populations (<italic>N</italic> = 288 patients) and lymphocyte subpopulations (<italic>N</italic> = 92 patients) across all measures after ALS diagnosis. The vast majority of the cell populations were within the normal range, except for CD8<sup>+</sup> central memory (CM) cells, CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells and CD8<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells, which were above the normal range.</p><p>In the main cohort, the levels of leukocytes, neutrophils, and monocytes increased progressively over time, especially from 20 months after diagnosis onward (<xref ref-type="fig" rid="fig1">Figure 1</xref>). These trends were statistically significant, with or without adjustment for age and sex, and remained statistically significant after correction for multiple testing (<xref ref-type="table" rid="table1">Table 1</xref>) . In contrast, no clear temporal trend was noted for lymphocytes. These results remained largely similar when stratifying the patients by sex, site of onset, or presence of <italic>C9orf72</italic> expansions (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The levels of leukocytes, neutrophils, and monocytes increased, whereas the levels of lymphocytes decreased, after Riluzole treatment, compared with before such treatment (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Mean levels of leukocyte populations after a diagnosis of amyotrophic lateral sclerosis (ALS).</title><p>The black lines show measured levels of leukocyte populations for each patient. The blue lines and shadow areas show the mean levels of leukocyte populations with 95% confidence intervals. Pink areas indicate normal range. p for trend shows the p value of within-individual temporal change of each cell population after taking into account the relatedness of repeated measurements.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Levels of leukocyte populations from 3months before diagnosis of amyotrophic lateral sclerosis (ALS) onwards.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74065-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74065-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Temporal trend of leukocyte populations by sex, site of onset, and presence of C9orf72 expansions.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74065-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Temporal trend of leukocyte populations before and after Riluzole treatment.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74065-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Lymphocyte populations that differed from normal range.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74065-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Temporal trend of lymphocyte populations by sex.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74065-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Temporal trend of lymphocyte populations that differed by site of onset and presence of C9orf72 expansions.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74065-fig1-figsupp5-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Temporal changes of leukocyte populations after diagnosis of amyotrophic lateral sclerosis (ALS), a cohort study of 288 patients with ALS in Stockholm, Sweden<xref ref-type="table-fn" rid="table1fn3">†</xref>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="bottom">Cell type</th><th align="left" colspan="3" valign="bottom">Unadjusted</th><th align="left" colspan="3" valign="bottom">Adjusted<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></th></tr><tr><th align="left" valign="bottom">Coefficient</th><th align="left" valign="bottom">p value</th><th align="left" valign="bottom">FDR</th><th align="left" valign="bottom">Coefficient</th><th align="left" valign="bottom">p value</th><th align="left" valign="bottom">FDR</th></tr></thead><tbody><tr><td align="left" valign="bottom">Leukocyte (10<sup>9</sup>/l)</td><td align="char" char="." valign="bottom">0.19</td><td align="char" char="." valign="bottom"><bold>0.01</bold></td><td align="char" char="." valign="bottom"><bold>0.01</bold></td><td align="char" char="." valign="bottom">0.22</td><td align="char" char="hyphen" valign="bottom"><bold>2.4E−03</bold></td><td align="char" char="hyphen" valign="bottom"><bold>4.7E−03</bold></td></tr><tr><td align="left" valign="bottom">Neutrophil (10<sup>9</sup>/l)</td><td align="char" char="." valign="bottom">0.18</td><td align="char" char="hyphen" valign="bottom"><bold>3.6E−03</bold></td><td align="char" char="." valign="bottom"><bold>0.01</bold></td><td align="char" char="." valign="bottom">0.21</td><td align="char" char="hyphen" valign="bottom"><bold>1.5E−03</bold></td><td align="char" char="hyphen" valign="bottom"><bold>4.7E−03</bold></td></tr><tr><td align="left" valign="bottom">Lymphocyte (10<sup>9</sup>/l)</td><td align="char" char="hyphen" valign="bottom">3.7E−03</td><td align="char" char="." valign="bottom">0.73</td><td align="char" char="." valign="bottom">0.73</td><td align="char" char="hyphen" valign="bottom">4.1E−05</td><td align="char" char="." valign="bottom">1.00</td><td align="char" char="." valign="bottom">1.00</td></tr><tr><td align="left" valign="bottom">Monocyte (10<sup>9</sup>/l)</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom"><bold>0.03</bold></td><td align="char" char="." valign="bottom"><bold>0.04</bold></td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="hyphen" valign="bottom"><bold>4.2E−03</bold></td><td align="char" char="." valign="bottom"><bold>0.01</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Bold values denote statistical significance of p &lt; 0.05.</p></fn><fn id="table1fn2"><label>*</label><p>Adjusted for age at diagnosis and sex.</p></fn><fn id="table1fn3"><label>†</label><p>Linear mixed model was applied to derive the coefficient estimates, per year and p value for trend.</p></fn><fn><p>FDR: false discovery rate.</p></fn></table-wrap-foot></table-wrap><p>In the FlowC cohort, no clear temporal trend was noted for any lymphocyte subpopulation, although ALS patients demonstrated persistently higher proportions of CD8<sup>+</sup> CM, CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup>, and CD8<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells than the reference ranges (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). After adjustment for age and sex, there was a decreasing % of naive CD4<sup>+</sup> T cells whereas increasing %s of CD4<sup>+</sup> EMRA, CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>−</sup>, and CD8<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>−</sup> cells since ALS diagnosis (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Male patients showed lower levels of CD4<sup>+</sup>, naive CD4<sup>+</sup>, and Th2 of CD4<sup>+</sup> CM cells, but higher levels of CD4<sup>+</sup> effector memory (EM, CD4<sup>+</sup> EMRA, CD8<sup>+</sup>, CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>−</sup>, and CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells, compared with female patients, especially early stage after diagnosis (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>)). Patients with limb onset had lower levels of CD8<sup>+</sup> CM and CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells compared with patients with other site of onset, whereas carriers of <italic>C9orf72</italic> expansions had higher levels of natural killer (NK) cells and T cells, but lower levels of naive CD4<sup>+</sup> T cells and CD8<sup>+</sup> EM cells, than other patients (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>).</p></sec><sec id="s2-2"><title>Survival</title><p>During a median follow-up of 1.1 years, we observed 163 deaths or use of invasive ventilation among the 288 patients of the main cohort. No association was noted between the level of leukocytes, neutrophils, lymphocytes, or monocytes with risk of death (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). This result did not change after excluding patients diagnosed before the start of the Motor Neuron Disease (MND) Quality Registry, focusing on first cell measure only, or excluding patients with <italic>C9orf72</italic> expansions (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Per standard deviation (SD) increase of neutrophil-to-lymphocyte ratio (NLR), there was a higher risk of death (hazard ratio [HR] = 1.31, 95% confidence interval [CI]: 1.13–1.52).</p><p>In the FlowC cohort, we found higher NK cell counts and %s of Th2-diffrentiated CD4<sup>+</sup> CM cells to be associated with lower risk of death, whereas higher %s of CD4<sup>+</sup> EMRA cells and CD8<sup>+</sup> T cells were associated with higher risk of death (<xref ref-type="fig" rid="fig2">Figure 2</xref>). These results were largely similar after restricting the analysis to first measure of lymphocytes (data not shown) or after excluding patients with <italic>C9orf72</italic> expansions (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Forest plot of hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of lymphocyte populations with risk of death after a diagnosis of amyotrophic lateral sclerosis (ALS).</title><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of lymphocyte populations with risk of death after a diagnosis of amyotrophic lateral sclerosis (ALS).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74065-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74065-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The associations of lymphocyte populations with risk of death after a diagnosis of amyotrophic lateral sclerosis (ALS), after excluding patients with C9orf72 expansions.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74065-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Functional status and disease progression rate</title><p>In the main cohort, a higher level of leukocytes, neutrophils, or monocytes was associated with a lower Amyotrophic Lateral Sclerosis Functional Rating Scale – revised (ALSFRS-R) score measured at the time of sampling, whereas no such correlation was evident for lymphocyte counts (<xref ref-type="table" rid="table2">Table 2</xref>). There was, however, no association of leukocytes, neutrophils, lymphocytes, or monocytes with disease progression rate. Disease progression rate differed however between patients with different NLRs (e.g., p = 0.04, comparing group with above third tertile NLR to the group with below first tertile NLR). A greater longitudinal increase of leukocytes, neutrophils, and monocytes was associated with a greater longitudinal decline in ALSFRS-R score (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Cross-sectional correlations between leukocyte populations and amyotrophic lateral sclerosis (ALS) Functional Rating Scale-revised (ALSFRS-R) score and disease progression rate, a cohort study of 288 ALS patients in Stockholm, Sweden<xref ref-type="table-fn" rid="table2fn2"><sup>*</sup></xref>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="top">Cell type</th><th align="left" colspan="3" valign="top">ALSFRS-R</th><th align="left" colspan="3" valign="top">Progression rate</th></tr><tr><th align="left" valign="top">Coefficient</th><th align="left" valign="top">p value</th><th align="left" valign="top">FDR</th><th align="left" valign="top">Coefficient</th><th align="left" valign="top">p value</th><th align="left" valign="top">FDR</th></tr></thead><tbody><tr><td align="left" valign="top">Leukocyte (10<sup>9</sup>/l)</td><td align="char" char="." valign="top">−2.80</td><td align="char" char="hyphen" valign="top"><bold>4.0E−03</bold></td><td align="char" char="." valign="top"><bold>0.01</bold></td><td align="char" char="." valign="top">0.02</td><td align="char" char="." valign="top">0.74</td><td align="char" char="." valign="top">0.74</td></tr><tr><td align="left" valign="top">Neutrophil (10<sup>9</sup>/l)</td><td align="char" char="." valign="top">−3.10</td><td align="char" char="hyphen" valign="top"><bold>1.0E−03</bold></td><td align="char" char="hyphen" valign="top"><bold>4.0E−03</bold></td><td align="char" char="." valign="top">0.05</td><td align="char" char="." valign="top">0.33</td><td align="char" char="." valign="top">0.67</td></tr><tr><td align="left" valign="top">Lymphocyte (10<sup>9</sup>/l)</td><td align="char" char="." valign="top">1.48</td><td align="char" char="." valign="top">0.15</td><td align="char" char="." valign="top">0.15</td><td align="char" char="." valign="top">−0.08</td><td align="char" char="." valign="top">0.32</td><td align="char" char="." valign="top">0.67</td></tr><tr><td align="left" valign="top">Monocyte (10<sup>9</sup>/l)</td><td align="char" char="." valign="top">−2.75</td><td align="char" char="hyphen" valign="top"><bold>2.0E−03</bold></td><td align="char" char="hyphen" valign="top"><bold>4.0E−03</bold></td><td align="char" char="." valign="top">−0.03</td><td align="char" char="." valign="top">0.52</td><td align="char" char="." valign="top">0.69</td></tr></tbody></table><table-wrap-foot><fn><p>Bold values denote statistical significance of p &lt; 0.05.</p></fn><fn id="table2fn2"><label>*</label><p>Generalized estimating equation model was applied to derive the coefficient estimates and p values, with adjustment for age at diagnosis and sex. ALSFRS-R score ranges from 0 to 48, with higher score showing better motor function status. Progression rate indicates the decline of motor function per month.</p></fn><fn><p>FDR: false discovery rate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Associations between longitudinal changes in cell measures and longitudinal changes in Amyotrophic Lateral Sclerosis Functional Rating Scale – revised (ALSFRS-R) score, a cohort study of 288 patients with ALS in Stockholm, Sweden<xref ref-type="table-fn" rid="table3fn3"><sup>†</sup></xref>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="bottom">Cell type</th><th align="left" colspan="2" valign="bottom">Unadjusted</th><th align="left" colspan="2" valign="bottom">Adjusted<sup><xref ref-type="table-fn" rid="table3fn2">*</xref></sup></th></tr><tr><th align="left" valign="bottom">Coefficient</th><th align="left" valign="bottom">p value</th><th align="left" valign="bottom">Coefficient</th><th align="left" valign="bottom">p value</th></tr></thead><tbody><tr><td align="left" valign="bottom">Leukocyte (10<sup>9</sup>/l)</td><td align="char" char="." valign="bottom">−5.72</td><td align="char" char="." valign="bottom"><bold>0.010</bold></td><td align="char" char="." valign="bottom">−5.41</td><td align="char" char="." valign="bottom"><bold>0.012</bold></td></tr><tr><td align="left" valign="bottom">Neutrophil (10<sup>9</sup>/l)</td><td align="char" char="." valign="bottom">−4.05</td><td align="char" char="." valign="bottom"><bold>0.020</bold></td><td align="char" char="." valign="bottom">−3.85</td><td align="char" char="." valign="bottom"><bold>0.023</bold></td></tr><tr><td align="left" valign="bottom">Lymphocyte (10<sup>9</sup>/l)</td><td align="char" char="." valign="bottom">−0.49</td><td align="char" char="." valign="bottom">0.839</td><td align="char" char="." valign="bottom">−0.22</td><td align="char" char="." valign="bottom">0.925</td></tr><tr><td align="left" valign="bottom">Monocyte (10<sup>9</sup>/l)</td><td align="char" char="." valign="bottom">−12.90</td><td align="char" char="." valign="bottom"><bold>0.001</bold></td><td align="char" char="." valign="bottom">−12.14</td><td align="char" char="." valign="bottom"><bold>0.001</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Bold values denote statistical significance of p &lt; 0.05.</p></fn><fn id="table3fn2"><label>*</label><p>Adjusted for age at diagnosis and sex.</p></fn><fn id="table3fn3"><label>†</label><p>Generalized estimating equation model was applied to derive the coefficient estimates and p values, per unit change of log-transformed leukocyte counts.</p></fn></table-wrap-foot></table-wrap><p>In the FlowC cohort, none of the lymphocyte subtypes was associated with ALSFRS-R score or disease progression rate measured at the time of sampling (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>).</p></sec><sec id="s2-4"><title>Sensitivity analysis for ongoing infection</title><p>We excluded 15 patients in the main cohort who had been sampled with the presence of infection. The results on risk of death, ALSFRS-R score and disease progression rate remained similar although some results lost statistical significance (<xref ref-type="supplementary-material" rid="supp7 supp8">Supplementary files 7 and 8</xref>). There was no patient with sampling during ongoing infection in the FlowC cohort.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We here report a longitudinal cohort study of temporal dynamics of white blood cell populations in 288 ALS patients in Stockholm, Sweden. We found higher counts of blood leukocytes, neutrophils, and monocytes to be associated with a lower functional status, but not with the risk of death after ALS diagnosis or disease progression rate. In a subsample of 92 patients, we found that higher NK cell counts and proportions of Th2-diffrentiated CD4<sup>+</sup> T cells were associated with a lower risk of death, whereas higher counts of CD8<sup>+</sup> T cells and proportions of CD4<sup>+</sup> EMRA T cells were associated with higher mortality risk.</p><p>ALS patients demonstrated gradually increasing counts of leukocytes, neutrophils, and monocytes over time since diagnosis. Benjamin et al. also reported increasing counts of leukocytes and neutrophils in ALS patients (<xref ref-type="bibr" rid="bib33">Murdock et al., 2017</xref>). Accumulating monocytes have also been shown in the cervical and lumbar spinal cord of ALS model over time (<xref ref-type="bibr" rid="bib52">Zondler et al., 2016</xref>). The finding that peripheral leukocytes, neutrophils, and monocytes were correlated to ALSFRS-R, but not progression rate or survival, indicates that these leukocyte subtypes may serve better as markers for functional status than prognosis. A previous study also found CD16 expression on neutrophils and nonclassical monocytes to correlate with ALS disease severity (<xref ref-type="bibr" rid="bib31">McGill et al., 2020</xref>). As neutrophils and monocytes have phagocytic function, increased levels of circulating neutrophils and monocytes might indicate enhanced muscle damage, explaining the correlation with deteriorating functional status. It has also been reported that circulating monocytes from ALS patients preferentially differentiate to a M1 proinflammatory phenotype and produce more interleukin 6 and tumor necrosis factor α, compared with monocytes from healthy controls (<xref ref-type="bibr" rid="bib11">Du et al., 2020</xref>). Regardless, although it has been proposed that peripheral neutrophils and monocytes are recruited to the CNS through a disrupted brain–blood barrier (BBB) and affect the disease progression of experimental ALS through secreting proinflammatory cytokines and influencing other cells (<xref ref-type="bibr" rid="bib32">Murdock et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Butovsky et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Zamudio et al., 2020</xref>), the functional relevance in human ALS is still unclear (<xref ref-type="bibr" rid="bib52">Zondler et al., 2016</xref>; <xref ref-type="bibr" rid="bib1">Ajami et al., 2007</xref>).</p><p>NLR has been considered a prognostic marker in many diseases, such as cancer (<xref ref-type="bibr" rid="bib2">Akinci Ozyurek et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Bowen et al., 2017</xref>) and cardiovascular disease (<xref ref-type="bibr" rid="bib19">Kim et al., 2018</xref>), which may indicate the involvement of complex coordination between different immune response pathways in the disease progression. Previous studies have also demonstrated a negative association between NLR and survival in ALS patients (<xref ref-type="bibr" rid="bib9">Choi et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Wei et al., 2022</xref>). Our study also found that a higher NLR was associated with a higher risk of death. However, the relation between NLR and disease progression rate of ALS is less consistently reported between studies (<xref ref-type="bibr" rid="bib9">Choi et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Wei et al., 2022</xref>), although we did find a higher NLR to be associated with a greater disease progression rate.</p><p>We found a higher level of blood-borne NK cells to be associated with a lower risk of death after ALS diagnosis. NK cells are considered a critical part of the innate immunity and function through lysing infected, oncogenic, apoptotic, and major histocompatibility complex (MHC) class I‐deficient cells (<xref ref-type="bibr" rid="bib47">Vivier et al., 2011</xref>). Although NK cells are known to penetrate BBB and interact with microglia, astroglia, and neurons (<xref ref-type="bibr" rid="bib45">Shi et al., 2011</xref>), the role of NK cells in disease progression of ALS has rarely been addressed. NK cells may exert a cytotoxic role in the brain by its natural function, as suggested by a study showing that depletion of NK cells prolonged survival in ALS mouse models (<xref ref-type="bibr" rid="bib12">Garofalo et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Murdock et al., 2021a</xref>). As infiltration of NK cells to CNS may lead to a decrease in peripheral NK populations, the protective role of higher peripheral NK cells against risk of death, as observed in the present study, might be partly attributable to a lower level of its infiltration to the CNS. On the other hand, NK cells may indeed also play a neuroprotective role. A previous study showed that lower levels of CD56<sup>bright</sup> NK cells in the CSF were associated with faster progression in ALS patients (<xref ref-type="bibr" rid="bib42">Rolfes et al., 2021</xref>). Additionally, findings from experimental autoimmune encephalomyelitis, a model of multiple sclerosis, showed NK cells to suppress neuroinflammation, diminish tissue damage, and protect motoneurons (<xref ref-type="bibr" rid="bib16">Huang et al., 2006</xref>; <xref ref-type="bibr" rid="bib14">Hammarberg et al., 2000</xref>). Patients with multiple sclerosis have also been shown to experience clinical improvement through NK cell expansions (<xref ref-type="bibr" rid="bib43">Segal, 2007</xref>). NK cells have also been shown to exert a protective role in brain by removing viral infection and activated microglia (<xref ref-type="bibr" rid="bib45">Shi et al., 2011</xref>).</p><p>We also found that higher Th2 differentiation of CD4<sup>+</sup> T cells was associated with a lower risk of death after ALS diagnosis, corroborating previous findings of the neuroprotective role of CD4<sup>+</sup> T cells in ALS (<xref ref-type="bibr" rid="bib4">Beers et al., 2008</xref>; <xref ref-type="bibr" rid="bib18">Jones et al., 2015</xref>). Animal studies have suggested Th1 and Th17 cells to promote neuroinflammation by producing proinflammatory cytokines and enhancing microglia-mediated neurotoxic effects (<xref ref-type="bibr" rid="bib36">Murphy et al., 2010</xref>) whereas Th2 cells and regulatory T cells (Tregs) to suppress neuroinflammation by producing anti-inflammatory cytokines and enhancing microglia-mediated neuroprotective effects (<xref ref-type="bibr" rid="bib13">Gendelman and Appel, 2011</xref>; <xref ref-type="bibr" rid="bib5">Beers et al., 2011</xref>). Although not statistically significant, our study indeed found a trend for Th1-differentiatated CD4<sup>+</sup> CM cells and Th17-differentiated CD4<sup>+</sup> CM cells to be positively associated with the risk of death after ALS diagnosis.</p><p>A novel finding of the present study is that higher proportions of CD8<sup>+</sup> T cells and CD4<sup>+</sup> EMRA T cells were associated with a higher risk of death after ALS diagnosis. The precise underlying mechanisms linking together these cell types with ALS survival are unclear. However, previous animal study showed that activated CD8<sup>+</sup> T cells were present in CNS of <italic>SOD1<sup>G93A</sup></italic> ALS model at the symptomatic stage, and that selective deletion of CD8<sup>+</sup> T cells could increase the survival of motoneurons whereas coculture motoneurons with mutant SOD1-expressing CD8<sup>+</sup> T lymphocytes could selectively kill the motoneurons via Fas and granzyme pathways (<xref ref-type="bibr" rid="bib10">Coque et al., 2019</xref>). Previous studies also indicated that CD4<sup>+</sup> EMRA cells could demonstrate cytotoxic features and express the chemokine receptor CX3CR1 in the setting of Dengue virus infection (<xref ref-type="bibr" rid="bib49">Weiskopf et al., 2015</xref>), which are associated with cytotoxic lymphocytes with cytoplasmic granules containing perforin and granzymes (<xref ref-type="bibr" rid="bib37">Nishimura et al., 2002</xref>). Further studies are clearly needed to study more in detail the functional relevance of CD8<sup>+</sup> and CD4<sup>+</sup> EMRA T cells in ALS.</p><p>Expansions in <italic>C9orf72</italic>, the most common genetic cause of ALS, have been shown to be associated with immune features (<xref ref-type="bibr" rid="bib23">Lai and Ichida, 2019</xref>), including activation of microglia and elevated levels of peripheral inflammatory cytokines (<xref ref-type="bibr" rid="bib46">Trageser et al., 2019</xref>). In our study, although patients with or without <italic>C9orf72</italic> expansions did not differ greatly in terms of major leukocyte populations, patients with <italic>C9orf72</italic> expansions appeared to display changes in certain lymphocyte subpopulations including NK, T, naive CD4<sup>+</sup> T, and CD8<sup>+</sup> EM cells compared with patients without such expansions. Because of the relatively small number of patients with <italic>C9orf72</italic> expansions in the study, these results should however be interpreted with caution until validated further.</p><p>Sex-based immunological difference might exist in response to external and internal antigens, contributing potentially to the variations in the incidence of autoimmune diseases and malignancies as well as the difference in response to vaccines between men and women (<xref ref-type="bibr" rid="bib20">Klein and Flanagan, 2016</xref>). Murdock et al. also demonstrated sex-specific effect of NK cells and neutrophils in ALS (<xref ref-type="bibr" rid="bib34">Murdock et al., 2021a</xref>; <xref ref-type="bibr" rid="bib35">Murdock et al., 2021b</xref>). In the present study, we found that men and women showed different longitudinal trajectories of some lymphocyte subpopulations but not leukocyte populations. Although these findings need to be validated, they add on the evidence base to support a potential sex-specific immune response in ALS and ALS as a heterogenous disease.</p><p>Our study is the first, to our knowledge, to report the role of a comprehensive list of immune cells, including neutrophils, lymphocytes, monocytes, and detailed T-cell phenotypes, on the prognosis of ALS. The strengths of the present study are the large number of ALS patients which were representative of all ALS patients in the source population, the rich information on disease characteristics including genetic causes, the long (up to 5 years after diagnosis) and complete follow-up (through the MND Quality Registry), the availability of both routine cell counts and detailed lymphocyte phenotyping, as well as the access to repeated measures over time. The study also has limitations. First, the main cohort was heterogeneous in terms of the numbers of cell measurements and the time intervals between measurements, as the timing of blood sampling was not predefined. Indication bias due to, for example, ongoing infections might therefore be a concern. The sensitivity analysis excluding all samples taken at the time of infections provided however rather similar results. Except for infection, other conditions such as immune diseases and allergies could also affect immune cell populations and should ideally also have been taken into account in the analysis. Further, the longitudinal analysis of cell counts should be interpreted with caution because not all patients contributed repeated cell measurements. This is however an unavoidable problem for any longitudinal study of ALS patients, given the high mortality rate of this patient group. Regardless, when focusing on the first cell measures, we obtained similar results as in the main analysis. It would therefore be interesting to compare ALS with other diseases, especially other neurodegenerative diseases, regarding the studied cell counts, in terms of both their longitudinal trajectories during disease course and their prognostic values in predicting patient outcome. Further, the FITMaN panel does not include B-cell subtypes or Treg cells, which await to be studied further. Finally, causal inferences on the functional implications of the reported associations are not possible due to the observational study design.</p><p>In conclusion, our findings suggest a dual role of immune responses in ALS prognosis, where neutrophils and monocytes primarily reflect functional status whereas different T lymphocyte populations act as prognostic markers for survival. These findings provide additional insights for cell-based therapy in prolonging survival in ALS.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Study cohort</title><p>The Swedish Motor Neuron Disease (MND) Quality Registry was established in 2015, collecting information on clinical characteristics, biological test results, and quality of life outcomes from &gt;80% of MND patients in Sweden (<xref ref-type="bibr" rid="bib25">Longinetti et al., 2018</xref>). Since 2017, the MND Quality Registry has included 99% of MND patients in the Stockholm area among whom 97.1% are diagnosed with ALS. All ALS diagnoses were made by a specialist in neurology and followed up by a neuromuscular specialist, and met the diagnostic requirement of definite, probable, probable laboratory supported, or possible ALS according to the revised El Escorial criteria (<xref ref-type="bibr" rid="bib26">Ludolph et al., 2015</xref>; <xref ref-type="bibr" rid="bib7">Brooks et al., 2000</xref>). To ensure the accuracy of diagnosis, all patients in the registry are re-evaluated annually to update diagnosis, whenever needed.</p><p>Through the MND Quality Registry, we first identified 420 patients with ALS diagnosed from the start of the registry until October 7, 2020, in Stockholm. We reviewed the medical records of these patients to identify information on peripheral leukocyte populations (i.e., differential leukocyte counts). During this process, we excluded 12 patients who were not diagnosed at the ALS Research and Care Center, Karolinska University Hospital – the only tertiary referral center for ALS in Stockholm, three patients with unknown time of symptom onset, 82 patients lacking leukocyte counts, and 35 patients with counts outside of the stipulated observation period (i.e., from 3 months before date of diagnosis until October 7, 2020). The final analysis cohort included 288 patients (68.6%), with at least one recorded differential leukocyte count during the observation period. The included patients did not differ significantly in terms of demographic and clinical characteristics from the excluded patients (<xref ref-type="table" rid="table4">Table 4</xref>). About half of the patients had a single measurement of leukocytes whereas the other half had been sampled two or more times.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Characteristics of the 288 patients with amyotrophic lateral sclerosis (ALS) included in the study, compared with the entire population of ALS patients during the study period in Stockholm, Sweden.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Characteristics</th><th align="left" valign="bottom">Patients included in the study (<italic>N</italic> = 288)</th><th align="left" valign="bottom">All patients in Stockholm (<italic>N</italic> = 420)</th><th align="left" valign="bottom">p value for difference<xref ref-type="table-fn" rid="table4fn1"><sup>*</sup></xref></th></tr></thead><tbody><tr><td align="left" valign="bottom">Sex, <italic>N</italic> (%)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">0.48</td></tr><tr><td align="left" valign="bottom"> Female</td><td align="char" char="." valign="bottom">134 (47%)</td><td align="char" char="." valign="bottom">201 (48%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Male</td><td align="char" char="." valign="bottom">154 (53%)</td><td align="char" char="." valign="bottom">219 (52%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" colspan="2" valign="bottom">Age at diagnosis, years</td><td align="left" valign="bottom"/><td align="left" valign="bottom">0.02</td></tr><tr><td align="left" valign="bottom"> Median (Q1, Q3)</td><td align="char" char="." valign="bottom">65 (56, 71)</td><td align="char" char="." valign="bottom">66 (57, 72)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" colspan="2" valign="bottom">Diagnostic delay, months</td><td align="left" valign="bottom"/><td align="left" valign="bottom">0.94</td></tr><tr><td align="left" valign="bottom"> Median (Q1, Q3)</td><td align="char" char="." valign="bottom">12.30 (7.88, 19.93)</td><td align="char" char="." valign="bottom">12.35 (7.59, 20.54)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene mutation, <italic>N</italic> (%)<sup><xref ref-type="table-fn" rid="table4fn2">†</xref></sup></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1.00</td></tr><tr><td align="left" valign="bottom"> <italic>SOD1</italic></td><td align="char" char="." valign="bottom">7 (2.88%)</td><td align="char" char="." valign="bottom">9 (2.56%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> <italic>C9orf72</italic></td><td align="char" char="." valign="bottom">22 (9.05%)</td><td align="char" char="." valign="bottom">30 (8.55%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Other</td><td align="char" char="." valign="bottom">4 (1.65%)</td><td align="char" char="." valign="bottom">5 (1.42%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" colspan="2" valign="bottom">Site of onset, <italic>N</italic> (%)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">0.26</td></tr><tr><td align="left" valign="bottom"> Limb</td><td align="char" char="." valign="bottom">182 (63%)</td><td align="char" char="." valign="bottom">250 (60%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Bulbar</td><td align="char" char="." valign="bottom">78 (27%)</td><td align="char" char="." valign="bottom">118 (28%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Other</td><td align="char" char="." valign="bottom">20 (7%)</td><td align="char" char="." valign="bottom">32 (8%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Missing</td><td align="char" char="." valign="bottom">8 (3%)</td><td align="char" char="." valign="bottom">20 (5%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" colspan="2" valign="bottom">Family history, <italic>N</italic> (%)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">0.19</td></tr><tr><td align="left" valign="bottom"> Yes</td><td align="char" char="." valign="bottom">19 (7%)</td><td align="char" char="." valign="bottom">30 (7%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> No</td><td align="char" char="." valign="bottom">144 (50%)</td><td align="char" char="." valign="bottom">201 (48%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Not clear</td><td align="char" char="." valign="bottom">3 (1%)</td><td align="char" char="." valign="bottom">7 (2%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Missing</td><td align="char" char="." valign="bottom">122 (42%)</td><td align="char" char="." valign="bottom">182 (43%)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" colspan="2" valign="bottom">No. of measurements for cell count (%)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">–</td></tr><tr><td align="left" valign="bottom"> One</td><td align="char" char="." valign="bottom">146 (51%)</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Two</td><td align="char" char="." valign="bottom">75 (26%)</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Three</td><td align="char" char="." valign="bottom">35 (12%)</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"> Four or more</td><td align="char" char="." valign="bottom">32 (11%)</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom"> </td></tr></tbody></table><table-wrap-foot><fn id="table4fn1"><label>*</label><p>p value for the differences between patients included in the study and patients not included in the study; Wilcoxon rank sum test was used for the comparison of continuous variables whereas chi-square test was used for the comparison of categorical variables.</p></fn><fn id="table4fn2"><label>†</label><p>Results available for 243 of the 288 patients included in the study, and 351 of the entire 420 patients in Stockholm.</p></fn></table-wrap-foot></table-wrap><p>Among the ALS patients diagnosed at the Karolinska University Hospital and with a date of symptom onset (<italic>N</italic> = 405), we further performed flow cytometry in 92 patients (‘FlowC cohort’) to determine lymphocyte subpopulations (i.e., T, B, and NK cells) as well as an extended T lymphocyte panel ‘FITMaN’ – an internationally standardized panel reported by the Flow Immunophenotyping Technical Meeting at NIH (<xref ref-type="bibr" rid="bib27">Maecker et al., 2012</xref>). Compared to the main study cohort, patients of the FlowC cohort were slightly younger and more likely to have a limb onset (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In both the main and FlowC cohorts, we followed the ALS patients from date of diagnosis or first cell measurement (differential leukocyte counts or FlowC), whichever came later, until occurrence of the outcome of interest (i.e., death or use of invasive ventilation) or October 7, 2020, whichever came first.</p></sec><sec id="s4-2"><title>Blood samples and flow cytometric analysis</title><p>All samples were freshly collected. The sample processing and analyzing procedures were according to the validated protocol at the Departments of Clinical Chemistry (differential leukocyte counts) and Clinical Immunology and Transfusion Medicine (FlowC), Karolinska University Hospital. All analyses were performed during daytime, within 24 hr of sampling. Differential leukocyte counts were done on a Sysmex XN-9000 (Sysmex, Kobe, Japan). FlowC was implemented in clinical routine based on the standardized phenotyping panel by the Human Immunophenotyping Consortium with a set of defined 8-color antibody cocktails (<xref ref-type="bibr" rid="bib27">Maecker et al., 2012</xref>). The experiments were performed on a triple-laser Beckman Coulter Gallios and analyzed by Kaluza Software (Beckman Coulter, Brea, CA).</p><p>Differential leukocyte counts included neutrophils, lymphocytes, monocytes, eosinophils, and basophils. We did not include eosinophils and basophils in the analysis as they in most cases were low to undetectable. In addition to studying leukocytes individually, we also analyzed NLR as suggested by previous studies (<xref ref-type="bibr" rid="bib9">Choi et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Wei et al., 2022</xref>). The FITMaN panel included measures of 23 lymphocyte subpopulations, including (1) counts of B cells, NK cells, and T cells; (2) %s of CD4<sup>+</sup> and CD8<sup>+</sup> T cell subtypes (i.e., naive, CM, EM, and effector memory cells re-expressing CD45RA [EMRA] T cells based on CCR7 and CD45RA expression, as well as Th1, Th2, and Th17 of CM and EM CD4<sup>+</sup> T cells based on CXCR3 and CCR6 expression); and (3) %s of subtypes of activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells based on the expression of HLA-DR and CD38 (i.e., CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>−</sup> cells, CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells, CD8<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>−</sup> cells, and CD8<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells). T cells were gated from a lymphocyte (FCS/SSC) gate as cells expressing CD45 and CD3. The unit of cell count was 10<sup>9</sup>/l whereas the %s were expressed as the proportions of the immune cell populations out of their parent populations. The normal references for leukocytes (main cohort) were reported by the Department of Clinical Chemistry, Karolinska University Hospital, based on the Nordic Reference Interval Project (NORIP) (<xref ref-type="bibr" rid="bib38">Nordin et al., 2004</xref>) (leukocyte: 3.5–8.8; neutrophil: 1.6–5.9; lymphocyte: 1.1–3.5; monocyte: 0.2–0.8; 10<sup>9</sup>/l). The reference values for FlowC were reported in the form of 5th to 95th percentiles using reference normal ranges obtained from 50 healthy adults. All cell counts and %s were retrieved from patient medical records.</p></sec><sec id="s4-3"><title>Outcomes of interest</title><p>The primary study outcome was risk of death or use of invasive ventilation after ALS diagnosis, identified from the MND Quality Registry. The secondary study outcomes included functional status measured through the ALSFRS-R and disease progression rate. ALSFRS-R is a questionnaire-based scale that measures the motor function and disease severity of ALS patients and is considered the gold standard measure of disability progression (<xref ref-type="bibr" rid="bib28">Makary et al., 2021</xref>). Higher ALSFRS-R score indicates better functional status. We acquired information on all available ALSFRS-R scores for the ALS patients from the MND Quality Registry. Progression rate measures the rate of ALSFRS-R decline and were calculated by dividing the difference between 48 (the full score) and measured ALSFRS-R score at a specific time point by the time difference between time of symptom onset to the measurement time of ALSFRS-R (in months). Progression rate is an independent prognostic predictor for ALS (<xref ref-type="bibr" rid="bib22">Labra et al., 2016</xref>).</p></sec><sec id="s4-4"><title>Other clinical characteristics</title><p>Data on sex, age at diagnosis, diagnostic delay, gene mutation, site of onset, family history, and body mass index (BMI) were collected from the MND Quality Registry or medical records. Diagnostic delay was calculated as time difference between date of onset and date of diagnosis. Site of onset was categorized as ‘limb’, ‘bulbar’, ‘other’, and ‘missing’. The definition of family history was based on whether a clear history of ALS existed among the relatives and categorized as ‘yes’, ‘no’, ‘not clear’, and ‘missing’. Genetic testing was offered to all patients with ALS around the time of diagnosis at the ALS Research and Care Center at Karolinska University Hospital. A total of 88 of the most common ALS-contributing genes, including <italic>SOD1</italic>, <italic>C9orf72</italic>, <italic>FUS</italic>, <italic>TARDBP</italic>, <italic>TBK1</italic>, <italic>OPTN</italic>, <italic>VCP</italic>, etc., were screened.</p></sec><sec id="s4-5"><title>Statistical analysis</title><p>To better understand the studied cell populations in ALS, we first performed a few analyses focusing on the different cell populations alone. We first calculated the mean levels of measured cell populations among ALS patients, by summarizing all measurements from 3 months before diagnosis until end of follow-up. To visualize the temporal patterns of the cell populations, we drew a trajectory line of all measurements for each cell type and each patient. We then used the locally estimated scatterplot smoothing curves with 95% CIs to show the temporal pattern of the predicted median level of each cell type after ALS diagnosis. If the CIs did not overlap with the normal ranges of the cell populations, we considered the observed levels among ALS patients to be statistically deviant from normal ranges. We also used linear mixed model to assess the within-individual temporal changes of cell populations after ALS diagnosis. In this analysis, we included a random intercept to account for the initial differences between individuals and adjusted for age at diagnosis and sex. We analyzed all ALS patients together first and then separately by sex, site of onset and presence of <italic>C9orf72</italic> expansions. Patients with <italic>C9orf72</italic> expansions have been suggested to demonstrate a different immune phenotype compared with ALS patients without such expansions (<xref ref-type="bibr" rid="bib40">Pinilla et al., 2021</xref>; <xref ref-type="bibr" rid="bib30">McCauley et al., 2020</xref>). To evaluate whether ALS treatment would influence the cell counts, we further visualized the temporal patterns of differential leukocyte counts before and after Riluzole treatment.</p><p>We next used Cox model to derive HR and 95% CI to assess the association of different cell populations with the risk of death, after adjustment for other prognostic indicators of ALS including age at diagnosis, sex, site of onset, diagnostic delay, ALSFRS-R score, time difference between the measure of ALSFRS-R score and diagnosis, BMI, and time difference between the measure of BMI and diagnosis. We used time since diagnosis as the underlying time scale and cluster robust variance estimation to account for dependence of repeated measurements. In this analysis, we log-transformed the counts of leukocytes, neutrophils, lymphocytes, and monocytes, as well as %s of CD4<sup>+</sup> EM cells, CD4<sup>+</sup> EMRA cells, Th2 of CD4<sup>+</sup> EM cells, Th17 of CD4<sup>+</sup> EM cells, Th2 of CD4<sup>+</sup> CM cells, CD8<sup>+</sup> T cells, CD8<sup>+</sup> CM cells, CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>−</sup> cells, CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells, CD8<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>−</sup> cells, and CD8<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells, to achieve a better normal distribution. Values of other cell populations were used as is (i.e., without transformation). For all markers, we estimated the effect size per SD increase. Because some patients had their first cell measurements after diagnosis, we also took into account left truncation in all analyses. Eight patients (3%) had missing values on site of onset and were excluded in the multivariable analysis where site of onset was adjusted for.</p><p>The proportional hazards assumption of the Cox model was assessed using the Schoenfeld residual test. After stratifying the analysis by site of onset which deviated from the assumption, the assumption became satisfied for all other variables. As HRs obtained in the stratified analysis were nearly the same as those obtained without stratification, for simplicity and consistency, we reported all findings from the original models (without stratification by site of onset).</p><p>Among the 288 patients, 57 (19.8%) were diagnosed before the start of the MND Quality Registry. In a sensitivity analysis, we excluded these patients with the aim to see if the results obtained in the main analysis would pertain to a cohort of incident patients. This analysis was not performed for the FlowC cohort as vast majority (<italic>N</italic> = 85) of the 92 patients were incident patients. We also conducted a sensitivity analysis by only focusing on the first cell measure of each patient to examine whether the main results would differ after removal of repeated measurements. We then performed another sensitivity analysis by excluding patients with <italic>C9orf72</italic> expansions, to understand the influence of <italic>C9orf72</italic> expansions on the results.</p><p>We further used a generalized estimating equation (GEE) model to assess the correlations of cell populations with functional status (i.e., ALSFRS-R score) and disease progression rate measured at the same time as the cell markers. The GEE model considers the correlations between repeated measurements within the same individual. Like the survival analysis above, we used log-transformed values for some cell measures whereas original values for others and estimated the effect size per SD increase of the cell measures, after adjustment for age at diagnosis and sex. Additionally, we also used the GEE model to assess the correlations between longitudinal changes in differential leukocyte counts and the longitudinal changes in ALSFRS-R score.</p><p>Finally, to assess whether the results on cell measures and the study outcomes would be influenced by ongoing infections, we performed another sensitivity analysis after excluding all measurements taken during an ongoing infection. This was done by reviewing medical records of all patients to see if at the time of blood sampling the patient had a high count of leukocyte (&gt;8.8 × 10<sup>9</sup>/l), a diagnosis of any infectious disease, specific tests for infection, or self-reported infectious symptoms.</p><p>All analyses were performed using R 3.6.2. A two-sided p value of &lt;0.05 was considered statistically significant. To correct for multiple testing, we also computed the Benjamini–Hochberg false discovery rate (<xref ref-type="bibr" rid="bib39">Pawitan et al., 2005</xref>).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Methodology, Supervision, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Methodology, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Funding acquisition, Methodology, Supervision, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The study was approved by the Regional Ethical Review Board in Stockholm (reference number: 2017/1895-31/1). Because of the register-based nature of the study, the requirement of informed consent was waived.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Characteristics of the 92 patients with amyotrophic lateral sclerosis (ALS) included in the analysis of FlowC test, compared with the entire population of ALS patients during the study period in Stockholm, Sweden.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-supp1-v1.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Mean levels of leukocyte subpopulations (<italic>N</italic> = 288 patients) and lymphocyte subpopulations (<italic>N</italic> = 92 patients) across all measures.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-supp2-v1.docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Temporal changes of lymphocyte populations after diagnosis of amyotrophic lateral sclerosis (ALS), analysis of 92 patients with FlowC test.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-supp3-v1.docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Associations of leukocyte populations with the risk of death after a diagnosis of amyotrophic lateral sclerosis (ALS), a cohort study of 288 patients with ALS in Stockholm, Sweden.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-supp4-v1.docx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Sensitivity analyses of the associations of leukocyte populations with risk of death after a diagnosis of amyotrophic lateral sclerosis (ALS), focusing on newly diagnosed ALS patients, first cell measure only, or excluding patients with C9orf72 expansions*.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-supp5-v1.docx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Cross-sectional correlations between lymphocyte populations and Amyotrophic Lateral Sclerosis Functional Rating Scale – revised (ALSFRS-R) score and disease progression rate, a cohort study of 92 ALS patients in Stockholm, Sweden*.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-supp6-v1.docx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Sensitivity analyses of the associations of leukocyte populations with Amyotrophic Lateral Sclerosis Functional Rating Scale – revised (ALSFRS-R) score and disease progression rate, after removing the the blood samples with potential ongoing infection*.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-supp7-v1.docx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Sensitivity analyses of associations of leukocyte populations with the risk of death after a diagnosis of amyotrophic lateral sclerosis (ALS), after removing the blood samples with potential ongoing infection*.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-supp8-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-74065-transrepform1-v1.docx"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Source code for Table 1 and 2.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74065-code1-v1.zip"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The original data are held by the Swedish Motor Neuron Disease Quality Registry and are not publicly available due to Swedish laws. However, any researcher who is interested can access the data by obtaining an ethical approval from regional ethical review board. Detailed information of the Swedish Ethical Review Authority can be found at <ext-link ext-link-type="uri" xlink:href="https://etikprovningsmyndigheten.se">https://etikprovningsmyndigheten.se</ext-link>. Anonymized data that support the findings of this study are available on reasonable request from the corresponding authors, in agreement with European regulations and Regional Ethical Review Board in Sweden. One source file containing R code (Source code 1) for table 1 and 2 has been provided.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the European Research Council (ERC) Starting Grant (MegaALS, No. 802091), the Swedish Research Council (No. 2019-01088), Karolinska Institutet (Strategic Research Area in Epidemiology and Senior Researcher Award), and China Scholarship Council. The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajami</surname><given-names>B</given-names></name><name><surname>Bennett</surname><given-names>JL</given-names></name><name><surname>Krieger</surname><given-names>C</given-names></name><name><surname>Tetzlaff</surname><given-names>W</given-names></name><name><surname>Rossi</surname><given-names>FMV</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Local self-renewal can sustain CNS microglia maintenance and function throughout adult life</article-title><source>Nature Neuroscience</source><volume>10</volume><fpage>1538</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.1038/nn2014</pub-id><pub-id pub-id-type="pmid">18026097</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinci Ozyurek</surname><given-names>B</given-names></name><name><surname>Sahin Ozdemirel</surname><given-names>T</given-names></name><name><surname>Buyukyaylaci Ozden</surname><given-names>S</given-names></name><name><surname>Erdogan</surname><given-names>Y</given-names></name><name><surname>Kaplan</surname><given-names>B</given-names></name><name><surname>Kaplan</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR)in Lung Cancer Cases</article-title><source>Asian Pacific Journal of Cancer Prevention</source><volume>18</volume><fpage>1417</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.22034/APJCP.2017.18.5.1417</pub-id><pub-id pub-id-type="pmid">28612596</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beers</surname><given-names>DR</given-names></name><name><surname>Henkel</surname><given-names>JS</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yen</surname><given-names>AA</given-names></name><name><surname>Siklos</surname><given-names>L</given-names></name><name><surname>McKercher</surname><given-names>SR</given-names></name><name><surname>Appel</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis</article-title><source>PNAS</source><volume>103</volume><fpage>16021</fpage><lpage>16026</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607423103</pub-id><pub-id pub-id-type="pmid">17043238</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beers</surname><given-names>DR</given-names></name><name><surname>Henkel</surname><given-names>JS</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Appel</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS</article-title><source>PNAS</source><volume>105</volume><fpage>15558</fpage><lpage>15563</lpage><pub-id pub-id-type="doi">10.1073/pnas.0807419105</pub-id><pub-id pub-id-type="pmid">18809917</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beers</surname><given-names>DR</given-names></name><name><surname>Henkel</surname><given-names>JS</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>B</given-names></name><name><surname>Appel</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis</article-title><source>Brain</source><volume>134</volume><fpage>1293</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1093/brain/awr074</pub-id><pub-id pub-id-type="pmid">21596768</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>RC</given-names></name><name><surname>Little</surname><given-names>NAB</given-names></name><name><surname>Harmer</surname><given-names>JR</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Mirabelli</surname><given-names>LG</given-names></name><name><surname>Roller</surname><given-names>KD</given-names></name><name><surname>Breivik</surname><given-names>AM</given-names></name><name><surname>Signor</surname><given-names>E</given-names></name><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Khong</surname><given-names>HT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis</article-title><source>Oncotarget</source><volume>8</volume><fpage>32171</fpage><lpage>32189</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16291</pub-id><pub-id pub-id-type="pmid">28418870</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>BR</given-names></name><name><surname>Miller</surname><given-names>RG</given-names></name><name><surname>Swash</surname><given-names>M</given-names></name><name><surname>Munsat</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the World Federation of Neurology</article-title><source>Research Group on Motor Neuron Diseases</source><volume>1</volume><fpage>293</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1080/146608200300079536</pub-id><pub-id pub-id-type="pmid">11464847</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Gabriely</surname><given-names>G</given-names></name><name><surname>Lanser</surname><given-names>AJ</given-names></name><name><surname>Dake</surname><given-names>B</given-names></name><name><surname>Murugaiyan</surname><given-names>G</given-names></name><name><surname>Doykan</surname><given-names>CE</given-names></name><name><surname>Wu</surname><given-names>PM</given-names></name><name><surname>Gali</surname><given-names>RR</given-names></name><name><surname>Iyer</surname><given-names>LK</given-names></name><name><surname>Lawson</surname><given-names>R</given-names></name><name><surname>Berry</surname><given-names>J</given-names></name><name><surname>Krichevsky</surname><given-names>AM</given-names></name><name><surname>Cudkowicz</surname><given-names>ME</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>3063</fpage><lpage>3087</lpage><pub-id pub-id-type="doi">10.1172/JCI62636</pub-id><pub-id pub-id-type="pmid">22863620</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Hong</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Shin</surname><given-names>JY</given-names></name><name><surname>Suh</surname><given-names>YJ</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>428</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-57366-y</pub-id><pub-id pub-id-type="pmid">31949271</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coque</surname><given-names>E</given-names></name><name><surname>Salsac</surname><given-names>C</given-names></name><name><surname>Espinosa-Carrasco</surname><given-names>G</given-names></name><name><surname>Varga</surname><given-names>B</given-names></name><name><surname>Degauque</surname><given-names>N</given-names></name><name><surname>Cadoux</surname><given-names>M</given-names></name><name><surname>Crabé</surname><given-names>R</given-names></name><name><surname>Virenque</surname><given-names>A</given-names></name><name><surname>Soulard</surname><given-names>C</given-names></name><name><surname>Fierle</surname><given-names>JK</given-names></name><name><surname>Brodovitch</surname><given-names>A</given-names></name><name><surname>Libralato</surname><given-names>M</given-names></name><name><surname>Végh</surname><given-names>AG</given-names></name><name><surname>Venteo</surname><given-names>S</given-names></name><name><surname>Scamps</surname><given-names>F</given-names></name><name><surname>Boucraut</surname><given-names>J</given-names></name><name><surname>Laplaud</surname><given-names>D</given-names></name><name><surname>Hernandez</surname><given-names>J</given-names></name><name><surname>Gergely</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>T</given-names></name><name><surname>Raoul</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cytotoxic CD8T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons</article-title><source>PNAS</source><volume>116</volume><fpage>2312</fpage><lpage>2317</lpage><pub-id pub-id-type="doi">10.1073/pnas.1815961116</pub-id><pub-id pub-id-type="pmid">30674678</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Thonhoff</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Appel</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Increased activation ability of monocytes from ALS patients</article-title><source>Experimental Neurology</source><volume>328</volume><elocation-id>113259</elocation-id><pub-id pub-id-type="doi">10.1016/j.expneurol.2020.113259</pub-id><pub-id pub-id-type="pmid">32105709</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garofalo</surname><given-names>S</given-names></name><name><surname>Cocozza</surname><given-names>G</given-names></name><name><surname>Porzia</surname><given-names>A</given-names></name><name><surname>Inghilleri</surname><given-names>M</given-names></name><name><surname>Raspa</surname><given-names>M</given-names></name><name><surname>Scavizzi</surname><given-names>F</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name><name><surname>Bernardini</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Santoni</surname><given-names>A</given-names></name><name><surname>Limatola</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1773</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15644-8</pub-id><pub-id pub-id-type="pmid">32286313</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gendelman</surname><given-names>HE</given-names></name><name><surname>Appel</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Neuroprotective activities of regulatory T cells</article-title><source>Trends in Molecular Medicine</source><volume>17</volume><fpage>687</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2011.08.005</pub-id><pub-id pub-id-type="pmid">21996344</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammarberg</surname><given-names>H</given-names></name><name><surname>Lidman</surname><given-names>O</given-names></name><name><surname>Lundberg</surname><given-names>C</given-names></name><name><surname>Eltayeb</surname><given-names>SY</given-names></name><name><surname>Gielen</surname><given-names>AW</given-names></name><name><surname>Muhallab</surname><given-names>S</given-names></name><name><surname>Svenningsson</surname><given-names>A</given-names></name><name><surname>Lindå</surname><given-names>H</given-names></name><name><surname>van Der Meide</surname><given-names>PH</given-names></name><name><surname>Cullheim</surname><given-names>S</given-names></name><name><surname>Olsson</surname><given-names>T</given-names></name><name><surname>Piehl</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells</article-title><source>The Journal of Neuroscience</source><volume>20</volume><fpage>5283</fpage><lpage>5291</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-14-05283.2000</pub-id><pub-id pub-id-type="pmid">10884312</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henkel</surname><given-names>JS</given-names></name><name><surname>Beers</surname><given-names>DR</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Rivera</surname><given-names>AL</given-names></name><name><surname>Toennis</surname><given-names>KM</given-names></name><name><surname>Appel</surname><given-names>JE</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Moore</surname><given-names>DH</given-names></name><name><surname>Powell</surname><given-names>SZ</given-names></name><name><surname>Appel</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulatory T‐lymphocytes mediate amyotrophic lateral sclerosis progression and survival</article-title><source>EMBO Molecular Medicine</source><volume>5</volume><fpage>64</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1002/emmm.201201544</pub-id><pub-id pub-id-type="pmid">23143995</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>FD</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Pien</surname><given-names>GC</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Salazar-Mather</surname><given-names>TP</given-names></name><name><surname>He</surname><given-names>TT</given-names></name><name><surname>Weaver</surname><given-names>JT</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Biron</surname><given-names>CA</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system</article-title><source>FASEB Journal</source><volume>20</volume><fpage>896</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1096/fj.05-5465com</pub-id><pub-id pub-id-type="pmid">16675847</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Günther</surname><given-names>R</given-names></name><name><surname>Akgün</surname><given-names>K</given-names></name><name><surname>Hermann</surname><given-names>A</given-names></name><name><surname>Ziemssen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>e8</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-62756-8</pub-id><pub-id pub-id-type="pmid">32246039</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>KJ</given-names></name><name><surname>Lovett-Racke</surname><given-names>AE</given-names></name><name><surname>Walker</surname><given-names>CL</given-names></name><name><surname>Sanders</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CD4 + T Cells and Neuroprotection: Relevance to Motoneuron Injury and Disease</article-title><source>Journal of Neuroimmune Pharmacology</source><volume>10</volume><fpage>587</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1007/s11481-015-9625-x</pub-id><pub-id pub-id-type="pmid">26148561</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Eliot</surname><given-names>M</given-names></name><name><surname>Koestler</surname><given-names>DC</given-names></name><name><surname>Wu</surname><given-names>WC</given-names></name><name><surname>Kelsey</surname><given-names>KT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Association of Neutrophil-to-Lymphocyte Ratio With Mortality and Cardiovascular Disease in the Jackson Heart Study and Modification by the Duffy Antigen Variant</article-title><source>JAMA Cardiology</source><volume>3</volume><fpage>455</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2018.1042</pub-id><pub-id pub-id-type="pmid">29801037</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>SL</given-names></name><name><surname>Flanagan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sex differences in immune responses</article-title><source>Nature Reviews. Immunology</source><volume>16</volume><fpage>626</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.90</pub-id><pub-id pub-id-type="pmid">27546235</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komine</surname><given-names>O</given-names></name><name><surname>Yamanaka</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuroinflammation in motor neuron disease</article-title><source>Nagoya Journal of Medical Science</source><volume>77</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">26663933</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labra</surname><given-names>J</given-names></name><name><surname>Menon</surname><given-names>P</given-names></name><name><surname>Byth</surname><given-names>K</given-names></name><name><surname>Morrison</surname><given-names>S</given-names></name><name><surname>Vucic</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rate of disease progression: a prognostic biomarker in ALS</article-title><source>Journal of Neurology, Neurosurgery, and Psychiatry</source><volume>87</volume><fpage>628</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2015-310998</pub-id><pub-id pub-id-type="pmid">26152368</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>JD</given-names></name><name><surname>Ichida</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>C9ORF72 protein function and immune dysregulation in amyotrophic lateral sclerosis</article-title><source>Neuroscience Letters</source><volume>713</volume><elocation-id>134523</elocation-id><pub-id pub-id-type="doi">10.1016/j.neulet.2019.134523</pub-id><pub-id pub-id-type="pmid">31568865</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Peripheral and Central Nervous System Immune Response Crosstalk in Amyotrophic Lateral Sclerosis</article-title><source>Frontiers in Neuroscience</source><volume>14</volume><elocation-id>575</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2020.00575</pub-id><pub-id pub-id-type="pmid">32612503</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longinetti</surname><given-names>E</given-names></name><name><surname>Regodón Wallin</surname><given-names>A</given-names></name><name><surname>Samuelsson</surname><given-names>K</given-names></name><name><surname>Press</surname><given-names>R</given-names></name><name><surname>Zachau</surname><given-names>A</given-names></name><name><surname>Ronnevi</surname><given-names>L-O</given-names></name><name><surname>Kierkegaard</surname><given-names>M</given-names></name><name><surname>Andersen</surname><given-names>PM</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Ingre</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Swedish motor neuron disease quality registry</article-title><source>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</source><volume>19</volume><fpage>528</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1080/21678421.2018.1497065</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludolph</surname><given-names>A</given-names></name><name><surname>Drory</surname><given-names>V</given-names></name><name><surname>Hardiman</surname><given-names>O</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name><name><surname>Ravits</surname><given-names>J</given-names></name><name><surname>Robberecht</surname><given-names>W</given-names></name><name><surname>Shefner</surname><given-names>J</given-names></name><collab>WFN Research Group On ALS/MND</collab></person-group><year iso-8601-date="2015">2015</year><article-title>A revision of the El Escorial criteria - 2015</article-title><source>Amyotrophic Lateral Sclerosis &amp; Frontotemporal Degeneration</source><volume>16</volume><fpage>291</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.3109/21678421.2015.1049183</pub-id><pub-id pub-id-type="pmid">26121170</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maecker</surname><given-names>HT</given-names></name><name><surname>McCoy</surname><given-names>JP</given-names></name><name><surname>Nussenblatt</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Standardizing immunophenotyping for the Human Immunology Project</article-title><source>Nature Reviews. Immunology</source><volume>12</volume><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nri3158</pub-id><pub-id pub-id-type="pmid">22343568</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makary</surname><given-names>MM</given-names></name><name><surname>Weerasekara</surname><given-names>A</given-names></name><name><surname>Rodham</surname><given-names>H</given-names></name><name><surname>Hightower</surname><given-names>BG</given-names></name><name><surname>Tseng</surname><given-names>C-EJ</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Chew</surname><given-names>S</given-names></name><name><surname>Paganoni</surname><given-names>S</given-names></name><name><surname>Ratai</surname><given-names>E-M</given-names></name><name><surname>Zürcher</surname><given-names>NR</given-names></name><name><surname>Hooker</surname><given-names>JM</given-names></name><name><surname>Atassi</surname><given-names>N</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comparison of Two Clinical Upper Motor Neuron Burden Rating Scales in ALS Using Quantitative Brain Imaging</article-title><source>ACS Chemical Neuroscience</source><volume>12</volume><fpage>906</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.0c00772</pub-id><pub-id pub-id-type="pmid">33576234</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Muriana</surname><given-names>A</given-names></name><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>Francos-Quijorna</surname><given-names>I</given-names></name><name><surname>Olmos-Alonso</surname><given-names>A</given-names></name><name><surname>Osta</surname><given-names>R</given-names></name><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Navarro</surname><given-names>X</given-names></name><name><surname>Gomez-Nicola</surname><given-names>D</given-names></name><name><surname>López-Vales</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>25663</elocation-id><pub-id pub-id-type="doi">10.1038/srep25663</pub-id><pub-id pub-id-type="pmid">27174644</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCauley</surname><given-names>ME</given-names></name><name><surname>O’Rourke</surname><given-names>JG</given-names></name><name><surname>Yáñez</surname><given-names>A</given-names></name><name><surname>Markman</surname><given-names>JL</given-names></name><name><surname>Ho</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lall</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Muhammad</surname><given-names>AKMG</given-names></name><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>Landeros</surname><given-names>J</given-names></name><name><surname>Valencia</surname><given-names>V</given-names></name><name><surname>Harms</surname><given-names>M</given-names></name><name><surname>Arditi</surname><given-names>M</given-names></name><name><surname>Jefferies</surname><given-names>C</given-names></name><name><surname>Baloh</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>C9orf72 in myeloid cells suppresses STING-induced inflammation</article-title><source>Nature</source><volume>585</volume><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2625-x</pub-id><pub-id pub-id-type="pmid">32814898</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGill</surname><given-names>RB</given-names></name><name><surname>Steyn</surname><given-names>FJ</given-names></name><name><surname>Ngo</surname><given-names>ST</given-names></name><name><surname>Thorpe</surname><given-names>KA</given-names></name><name><surname>Heggie</surname><given-names>S</given-names></name><name><surname>Ruitenberg</surname><given-names>MJ</given-names></name><name><surname>Henderson</surname><given-names>RD</given-names></name><name><surname>McCombe</surname><given-names>PA</given-names></name><name><surname>Woodruff</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis</article-title><source>Brain Communications</source><volume>2</volume><elocation-id>fcaa013</elocation-id><pub-id pub-id-type="doi">10.1093/braincomms/fcaa013</pub-id><pub-id pub-id-type="pmid">33033799</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdock</surname><given-names>BJ</given-names></name><name><surname>Bender</surname><given-names>DE</given-names></name><name><surname>Segal</surname><given-names>BM</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The dual roles of immunity in ALS: injury overrides protection</article-title><source>Neurobiology of Disease</source><volume>77</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2015.02.017</pub-id><pub-id pub-id-type="pmid">25726748</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdock</surname><given-names>BJ</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Kashlan</surname><given-names>SR</given-names></name><name><surname>Little</surname><given-names>RJ</given-names></name><name><surname>Goutman</surname><given-names>SA</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression</article-title><source>JAMA Neurology</source><volume>74</volume><fpage>1446</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.2255</pub-id><pub-id pub-id-type="pmid">28973548</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdock</surname><given-names>BJ</given-names></name><name><surname>Famie</surname><given-names>JP</given-names></name><name><surname>Piecuch</surname><given-names>CE</given-names></name><name><surname>Raue</surname><given-names>KD</given-names></name><name><surname>Mendelson</surname><given-names>FE</given-names></name><name><surname>Pieroni</surname><given-names>CH</given-names></name><name><surname>Iniguez</surname><given-names>SD</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Goutman</surname><given-names>SA</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>NK cells associate with ALS in a sex- and age-dependent manner</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>147129</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.147129</pub-id><pub-id pub-id-type="pmid">33974561</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdock</surname><given-names>BJ</given-names></name><name><surname>Goutman</surname><given-names>SA</given-names></name><name><surname>Boss</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner</article-title><source>Neurology(R) Neuroimmunology &amp; Neuroinflammation</source><volume>8</volume><elocation-id>e953</elocation-id><pub-id pub-id-type="doi">10.1212/NXI.0000000000000953</pub-id><pub-id pub-id-type="pmid">33531377</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>AC</given-names></name><name><surname>Lalor</surname><given-names>SJ</given-names></name><name><surname>Lynch</surname><given-names>MA</given-names></name><name><surname>Mills</surname><given-names>KHG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis</article-title><source>Brain, Behavior, and Immunity</source><volume>24</volume><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2010.01.014</pub-id><pub-id pub-id-type="pmid">20138983</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Umehara</surname><given-names>H</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Yoneda</surname><given-names>O</given-names></name><name><surname>Hieshima</surname><given-names>K</given-names></name><name><surname>Kakizaki</surname><given-names>M</given-names></name><name><surname>Dohmae</surname><given-names>N</given-names></name><name><surname>Yoshie</surname><given-names>O</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>168</volume><fpage>6173</fpage><lpage>6180</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.12.6173</pub-id><pub-id pub-id-type="pmid">12055230</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordin</surname><given-names>G</given-names></name><name><surname>Mårtensson</surname><given-names>A</given-names></name><name><surname>Swolin</surname><given-names>B</given-names></name><name><surname>Sandberg</surname><given-names>S</given-names></name><name><surname>Christensen</surname><given-names>NJ</given-names></name><name><surname>Thorsteinsson</surname><given-names>V</given-names></name><name><surname>Franzson</surname><given-names>L</given-names></name><name><surname>Kairisto</surname><given-names>V</given-names></name><name><surname>Savolainen</surname><given-names>E-R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A multicentre study of reference intervals for haemoglobin, basic blood cell counts and erythrocyte indices in the adult population of the Nordic countries</article-title><source>Scandinavian Journal of Clinical and Laboratory Investigation</source><volume>64</volume><fpage>385</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1080/00365510410002797</pub-id><pub-id pub-id-type="pmid">15223702</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawitan</surname><given-names>Y</given-names></name><name><surname>Michiels</surname><given-names>S</given-names></name><name><surname>Koscielny</surname><given-names>S</given-names></name><name><surname>Gusnanto</surname><given-names>A</given-names></name><name><surname>Ploner</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>False discovery rate, sensitivity and sample size for microarray studies</article-title><source>Bioinformatics (Oxford, England)</source><volume>21</volume><fpage>3017</fpage><lpage>3024</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti448</pub-id><pub-id pub-id-type="pmid">15840707</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinilla</surname><given-names>G</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Floaters</surname><given-names>MK</given-names></name><name><surname>Pardo</surname><given-names>CA</given-names></name><name><surname>Rothstein</surname><given-names>J</given-names></name><name><surname>Ilieva</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Increased synthesis of pro-inflammatory cytokines in C9ORF72 patients</article-title><source>Amyotrophic Lateral Sclerosis &amp; Frontotemporal Degeneration</source><volume>22</volume><fpage>517</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1080/21678421.2021.1912100</pub-id><pub-id pub-id-type="pmid">33929933</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rentzos</surname><given-names>M</given-names></name><name><surname>Evangelopoulos</surname><given-names>E</given-names></name><name><surname>Sereti</surname><given-names>E</given-names></name><name><surname>Zouvelou</surname><given-names>V</given-names></name><name><surname>Marmara</surname><given-names>S</given-names></name><name><surname>Alexakis</surname><given-names>T</given-names></name><name><surname>Evdokimidis</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Alterations of T cell subsets in ALS: a systemic immune activation?</article-title><source>Acta Neurologica Scandinavica</source><volume>125</volume><fpage>260</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.2011.01528.x</pub-id><pub-id pub-id-type="pmid">21651502</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolfes</surname><given-names>L</given-names></name><name><surname>Schulte-Mecklenbeck</surname><given-names>A</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Vielhaber</surname><given-names>S</given-names></name><name><surname>Herty</surname><given-names>M</given-names></name><name><surname>Marten</surname><given-names>A</given-names></name><name><surname>Pfeuffer</surname><given-names>S</given-names></name><name><surname>Ruck</surname><given-names>T</given-names></name><name><surname>Wiendl</surname><given-names>H</given-names></name><name><surname>Gross</surname><given-names>CC</given-names></name><name><surname>Meuth</surname><given-names>SG</given-names></name><name><surname>Boentert</surname><given-names>M</given-names></name><name><surname>Pawlitzki</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation</article-title><source>Brain Communications</source><volume>3</volume><elocation-id>fcab157</elocation-id><pub-id pub-id-type="doi">10.1093/braincomms/fcab157</pub-id><pub-id pub-id-type="pmid">34405141</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The role of natural killer cells in curbing neuroinflammation</article-title><source>Journal of Neuroimmunology</source><volume>191</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.09.006</pub-id><pub-id pub-id-type="pmid">17904646</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheean</surname><given-names>RK</given-names></name><name><surname>McKay</surname><given-names>FC</given-names></name><name><surname>Cretney</surname><given-names>E</given-names></name><name><surname>Bye</surname><given-names>CR</given-names></name><name><surname>Perera</surname><given-names>ND</given-names></name><name><surname>Tomas</surname><given-names>D</given-names></name><name><surname>Weston</surname><given-names>RA</given-names></name><name><surname>Scheller</surname><given-names>KJ</given-names></name><name><surname>Djouma</surname><given-names>E</given-names></name><name><surname>Menon</surname><given-names>P</given-names></name><name><surname>Schibeci</surname><given-names>SD</given-names></name><name><surname>Marmash</surname><given-names>N</given-names></name><name><surname>Yerbury</surname><given-names>JJ</given-names></name><name><surname>Nutt</surname><given-names>SL</given-names></name><name><surname>Booth</surname><given-names>DR</given-names></name><name><surname>Stewart</surname><given-names>GJ</given-names></name><name><surname>Kiernan</surname><given-names>MC</given-names></name><name><surname>Vucic</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis</article-title><source>JAMA Neurology</source><volume>75</volume><elocation-id>681</elocation-id><pub-id pub-id-type="doi">10.1001/jamaneurol.2018.0035</pub-id><pub-id pub-id-type="pmid">29507931</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>FD</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>La Cava</surname><given-names>A</given-names></name><name><surname>Van Kaer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Organ-specific features of natural killer cells</article-title><source>Nature Reviews. Immunology</source><volume>11</volume><fpage>658</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1038/nri3065</pub-id><pub-id pub-id-type="pmid">21941294</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trageser</surname><given-names>KJ</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Herman</surname><given-names>FJ</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Pasinetti</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanisms of Immune Activation by c9orf72 Expansions in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia</article-title><source>Frontiers in Neuroscience</source><volume>13</volume><elocation-id>1298</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2019.01298</pub-id><pub-id pub-id-type="pmid">31920478</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Raulet</surname><given-names>DH</given-names></name><name><surname>Moretta</surname><given-names>A</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Yokoyama</surname><given-names>WM</given-names></name><name><surname>Ugolini</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Innate or adaptive immunity? The example of natural killer cells</article-title><source>Science (New York, N.Y.)</source><volume>331</volume><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1126/science.1198687</pub-id><pub-id pub-id-type="pmid">21212348</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Q-Q</given-names></name><name><surname>Hou</surname><given-names>Y-B</given-names></name><name><surname>Zhang</surname><given-names>L-Y</given-names></name><name><surname>Ou</surname><given-names>R-W</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y-P</given-names></name><name><surname>Shang</surname><given-names>H-F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Neutrophil-to-lymphocyte ratio in sporadic amyotrophic lateral sclerosis</article-title><source>Neural Regeneration Research</source><volume>17</volume><fpage>875</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.322476</pub-id><pub-id pub-id-type="pmid">34472488</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Bangs</surname><given-names>DJ</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Kolla</surname><given-names>RV</given-names></name><name><surname>De Silva</surname><given-names>AD</given-names></name><name><surname>de Silva</surname><given-names>AM</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity</article-title><source>PNAS</source><volume>112</volume><fpage>E4256</fpage><lpage>E4263</lpage><pub-id pub-id-type="doi">10.1073/pnas.1505956112</pub-id><pub-id pub-id-type="pmid">26195744</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamudio</surname><given-names>F</given-names></name><name><surname>Loon</surname><given-names>AR</given-names></name><name><surname>Smeltzer</surname><given-names>S</given-names></name><name><surname>Benyamine</surname><given-names>K</given-names></name><name><surname>Navalpur Shanmugam</surname><given-names>NK</given-names></name><name><surname>Stewart</surname><given-names>NJF</given-names></name><name><surname>Lee</surname><given-names>DC</given-names></name><name><surname>Nash</surname><given-names>K</given-names></name><name><surname>Selenica</surname><given-names>M-LB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model</article-title><source>Journal of Neuroinflammation</source><volume>17</volume><elocation-id>283</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-020-01952-9</pub-id><pub-id pub-id-type="pmid">32979923</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarei</surname><given-names>S</given-names></name><name><surname>Carr</surname><given-names>K</given-names></name><name><surname>Reiley</surname><given-names>L</given-names></name><name><surname>Diaz</surname><given-names>K</given-names></name><name><surname>Guerra</surname><given-names>O</given-names></name><name><surname>Altamirano</surname><given-names>PF</given-names></name><name><surname>Pagani</surname><given-names>W</given-names></name><name><surname>Lodin</surname><given-names>D</given-names></name><name><surname>Orozco</surname><given-names>G</given-names></name><name><surname>Chinea</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A comprehensive review of amyotrophic lateral sclerosis</article-title><source>Surgical Neurology International</source><volume>6</volume><elocation-id>171</elocation-id><pub-id pub-id-type="doi">10.4103/2152-7806.169561</pub-id><pub-id pub-id-type="pmid">26629397</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zondler</surname><given-names>L</given-names></name><name><surname>Müller</surname><given-names>K</given-names></name><name><surname>Khalaji</surname><given-names>S</given-names></name><name><surname>Bliederhäuser</surname><given-names>C</given-names></name><name><surname>Ruf</surname><given-names>WP</given-names></name><name><surname>Grozdanov</surname><given-names>V</given-names></name><name><surname>Thiemann</surname><given-names>M</given-names></name><name><surname>Fundel-Clemes</surname><given-names>K</given-names></name><name><surname>Freischmidt</surname><given-names>A</given-names></name><name><surname>Holzmann</surname><given-names>K</given-names></name><name><surname>Strobel</surname><given-names>B</given-names></name><name><surname>Weydt</surname><given-names>P</given-names></name><name><surname>Witting</surname><given-names>A</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Helferich</surname><given-names>AM</given-names></name><name><surname>Hengerer</surname><given-names>B</given-names></name><name><surname>Gottschalk</surname><given-names>K-E</given-names></name><name><surname>Hill</surname><given-names>O</given-names></name><name><surname>Kluge</surname><given-names>M</given-names></name><name><surname>Ludolph</surname><given-names>AC</given-names></name><name><surname>Danzer</surname><given-names>KM</given-names></name><name><surname>Weishaupt</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Peripheral monocytes are functionally altered and invade the CNS in ALS patients</article-title><source>Acta Neuropathologica</source><volume>132</volume><fpage>391</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1548-y</pub-id><pub-id pub-id-type="pmid">26910103</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74065.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tanzi</surname><given-names>Rudolph E</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.10.05.21264570" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.05.21264570"/></front-stub><body><p>Cui et al. colleagues carried out a longitudinal analysis of blood cell counts in a cohort of ALS patients and found increased numbers of neutrophils and monocytes, which negatively correlated with ALSFRS-R score, but not with rate of disease progression. They also found increased levels in NK and central memory TH2 T cells, which correlated with a lower risk of death. In contrast, increased levels of CD4 CD45RA effector memory and CD8 T cells were correlated with a higher risk of death. These findings have important implications for the pathogenesis of ALS as well as the development of immune-based ALS therapies targeting specific populations immune cells.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74065.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tanzi</surname><given-names>Rudolph E</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.05.21264570">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2021.10.05.21264570v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis: a longitudinal cohort study&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Catherine Dulac as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Please address:</p><p>&quot;Given these issues, one really would want to see disease controls, and how the different cell counts change in another disease. Finally, there is not discussion about how or whether treatments, or changes in treatment, could influence observed counts. &quot;</p><p>2. &quot;Levels of cell counts correlate with ALSFRSR but not disease progression. It would be interesting to know whether the change in cell counts correlate with changes in ALSFRSR.&quot;</p><p>3) &quot;The description of primary outcome is confusing, as this is typically referring to a single prespecified outcome and associated statistical analysis, whereas the paper initially focuses on longitudinal changes in cell counts before asking how difference in a large number of cell sets were or were not predictive of survival.&quot;</p><p>4) &quot;Sex has been identified as a determinant of immune system profiles in ALS (see PMIDs 33974561, 33531377, 32388062, 33715827, for example). Although the authors investigated the impact of C9orf72 and segment onset, it would be interesting to determine whether sex impacted immune profiles in this cohort.&quot;</p><p>5) &quot;A couple of studies have recently reported on the prognostic role of neutrophil-to-lymphocyte ratio in cross-sectional studies and in Asian ALS populations (PMIDs 31949271, 34472488). It would be insightful to determine whether these findings are replicated here.&quot;</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Levels of cell counts correlate with ALSFRSR but not disease progression. It would be interesting to know whether the change in cell counts correlate with changes in ALSFRSR.</p><p>The description of primary outcome is confusing, as this is typically referring to a single prespecified outcome and associated statistical analysis, whereas the paper initially focuses on longitudinal changes in cell counts before asking how difference in a large number of cell sets were or were not predictive of survival.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>(1) Sex has been identified as a determinant of immune system profiles in ALS (see PMIDs 33974561, 33531377, 32388062, 33715827, for example). Although the authors investigated the impact of C9orf72 and segment onset, it would be interesting to determine whether sex impacted immune profiles in this cohort.</p><p>(2) A couple of studies have recently reported on the prognostic role of neutrophil-to-lymphocyte ratio in cross-sectional studies and in Asian ALS populations (PMIDs 31949271, 34472488). It would be insightful to determine whether these findings are replicated here.</p><p>(3) The PMIDs 31949271, 34472488, 33974561, 33531377 are missing from the discussion.</p><p>(4) Additionally, T cells have been investigated in ALS: although a genetic model, the study by Coque et al. is very salient (PMID 30674678), in sporadic ALS patients (PMID 34405141).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74065.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Please address:</p><p>&quot;Given these issues, one really would want to see disease controls, and how the different cell counts change in another disease. Finally, there is not discussion about how or whether treatments, or changes in treatment, could influence observed counts. &quot;</p></disp-quote><p>Regarding disease control, we have now shown a figure about longitudinal changes of the studied cell populations in a cohort of 34 patients with multiple sclerosis measured during the same time period using the identical methodology at the Karolinska University Hospital.</p><p>Regarding treatment, as a vast majority (89.6%) of the ALS patients included in the study were treated with Riluzole, we have now added an analysis to show the cell counts before and after Riluzole treatment in the manuscript. Please see response to Reviewer 1 below.</p><disp-quote content-type="editor-comment"><p>2. &quot;Levels of cell counts correlate with ALSFRSR but not disease progression. It would be interesting to know whether the change in cell counts correlate with changes in ALSFRSR.&quot;</p></disp-quote><p>We have now added the suggested analysis in the manuscript. In brief, we found that a greater increase of leukocytes, neutrophils and monocytes was associated with a greater decline in ALSFRS-R score.</p><disp-quote content-type="editor-comment"><p>3) &quot;The description of primary outcome is confusing, as this is typically referring to a single prespecified outcome and associated statistical analysis, whereas the paper initially focuses on longitudinal changes in cell counts before asking how difference in a large number of cell sets were or were not predictive of survival.&quot;</p></disp-quote><p>The primary outcome of the study is risk of death (alternatively use of invasive ventilation). The secondary outcomes are ALSFRS-R score and disease progression rate. The longitudinal changes of cell counts were described to understand the temporal changes of the exposure (i.e., cell counts). We have now clarified these in the manuscript.</p><disp-quote content-type="editor-comment"><p>4) &quot;Sex has been identified as a determinant of immune system profiles in ALS (see PMIDs 33974561, 33531377, 32388062, 33715827, for example). Although the authors investigated the impact of C9orf72 and segment onset, it would be interesting to determine whether sex impacted immune profiles in this cohort.&quot;</p></disp-quote><p>We have now added a figure to show the sex-specific longitudinal changes of cell counts.</p><disp-quote content-type="editor-comment"><p>5) &quot;A couple of studies have recently reported on the prognostic role of neutrophil-to-lymphocyte ratio in cross-sectional studies and in Asian ALS populations (PMIDs 31949271, 34472488). It would be insightful to determine whether these findings are replicated here.&quot;</p></disp-quote><p>We have now added analysis for neutrophil-to-lymphocyte ratio in the manuscript. Please see response to Reviewer 2 below.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Levels of cell counts correlate with ALSFRSR but not disease progression. It would be interesting to know whether the change in cell counts correlate with changes in ALSFRSR.</p></disp-quote><p>Thank you for the good suggestion. We have now used generalized estimating equation model to evaluate the associations between changes in cell measures and changes in ALSFRS-R score (see Table 4). In brief, the results showed that a greater longitudinal increase of leukocyte, neutrophils and monocyte was associated with a greater longitudinal decline in ALSFRS-R score.</p><p>We have now added this new analysis in Methods and Results.</p><p>Page 17, paragraph 2:</p><p>“Additionally, we also used the GEE model to assess the correlations between longitudinal changes in differential leukocyte counts and the longitudinal changes in ALSFRS-R score.”</p><p>Page 6, paragraph 4:</p><p>“A greater longitudinal increase of leukocytes, neutrophils and monocytes was associated with a greater longitudinal decline in ALSFRS-R score (Table 4).”</p><disp-quote content-type="editor-comment"><p>The description of primary outcome is confusing, as this is typically referring to a single prespecified outcome and associated statistical analysis, whereas the paper initially focuses on longitudinal changes in cell counts before asking how difference in a large number of cell sets were or were not predictive of survival.</p></disp-quote><p>The primary outcome of the study is risk of death (alternatively use of invasive ventilation). The secondary outcomes are ALSFRS score and disease progression rate. The longitudinal changes of cell counts were described to show the temporal changes of the exposure (i.e., cell measurements). We have now clarified these in the manuscript.</p><p>Page 14, paragraph 2:</p><p>“The primary study outcome was risk of death or use of invasive ventilation after ALS diagnosis, identified from the MND Quality Registry. The secondary study outcomes included functional status measured through the Amyotrophic Lateral Sclerosis Functional Rating Scale – revised (ALSFRS-R) and disease progression rate.”</p><p>Page 15, paragraph 3:</p><p>“To better understand the studied cell populations in ALS, we first performed a few analyses focusing on the different cell populations alone. […] We then used the locally estimated scatterplot smoothing (LOESS) curves with 95% confidence intervals (CIs) to show the temporal pattern of the predicted median level of each cell type after ALS diagnosis…”</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>(1) Sex has been identified as a determinant of immune system profiles in ALS (see PMIDs 33974561, 33531377, 32388062, 33715827, for example). Although the authors investigated the impact of C9orf72 and segment onset, it would be interesting to determine whether sex impacted immune profiles in this cohort.</p></disp-quote><p>Thank you for the suggestion. We have now performed analysis to show the sex-specific longitudinal changes of the cell populations and added this new analysis to Methods and Results, including a new panel to Figure 1—figure supplement 1 and a new Figure 1—figure supplement 4.</p><p>Page 15, paragraph 3:</p><p>“We analyzed all ALS patients together first and then separately by sex, site of onset and presence of C9orf72 expansions.”</p><p>Page 5, paragraph 2:</p><p>“These results remained largely similar when stratifying the patients by sex, site of onset or presence of C9orf72 expansions (Figure 1—figure supplement 1).”</p><p>Page 5, paragraph 3:</p><p>“Male patients showed lower levels of CD4<sup>+</sup>, naïve CD4<sup>+</sup> and Th2 of CD4<sup>+</sup> CM cells, but higher levels of CD4<sup>+</sup> EM, CD4<sup>+</sup> EMRA, CD8<sup>+</sup>, CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>-</sup>, and CD4<sup>+</sup>HLA-DR<sup>+</sup>CD38<sup>+</sup> cells, compared with female patients, especially early stage after diagnosis (Figure 1—figure supplement 4).”</p><disp-quote content-type="editor-comment"><p>(2) A couple of studies have recently reported on the prognostic role of neutrophil-to-lymphocyte ratio in cross-sectional studies and in Asian ALS populations (PMIDs 31949271, 34472488). It would be insightful to determine whether these findings are replicated here.</p></disp-quote><p>Thank you for the suggestion. In the study by Choi et al. (PMID 31949271), ALS patients with the highest (above 3rd tertile) baseline neutrophil-to-lymphocyte ratio (NLR) were found to have a higher risk of death compared with patients with the lowest (below 1st tertile) baseline NLR (HR=1.60, 95%CI: 1.01–2.51, P = 0.041). However, no difference in disease progression rate was found between patients with different levels of NLR. In the study by Wei et al. (PMID 34472488), 1030 ALS patients were divided into three groups according to NLR: Group 1 (NLR &lt;2), Group 2 (NLR 2–3), and Group 3 (NLR &gt;3). The survival time differed between these groups with Group 3 showing the shortest survival. A 1-unit increase in NLR was associated with a higher mortality (HR=1.079, 95% CI: 1.016–1.146, P=0.014) whereas disease progression rate was also found to differ between the three groups.</p><p>We have now analyzed the association between NLR and risk of death in our study, and found that an increase in NLR was indeed associated with a higher risk of death (HR=1.31, 95% CI: 1.13-1.52 per SD increase in NLR). We also found that disease progression rate differed between patients with different NLRs (e.g., p=0.04, comparing group with above the 3<sup>rd</sup> tertile NLR to the group with below the 1<sup>st</sup> tertile NLR). We have now added this new analysis to Methods, Results, and Discussion (including citing the two references).</p><p>Page 13, paragraph 4:</p><p>“In addition to studying leukocytes individually, we also analyzed neutrophil-to-lymphocyte ratio (NLR) as suggested by previous studies<sup>23,24</sup>.”</p><p>Page 6, paragraph 2:</p><p>“Per SD increase of NLR, there was a higher risk of death (HR=1.31, 95% CI: 1.13-1.52).”</p><p>Page 6, paragraph 4:</p><p>“Disease progression rate differed however between patients with different NLRs (e.g., p=0.04, comparing group with above 3<sup>rd</sup> tertile NLR to the group with below 1<sup>st</sup> tertile NLR).”</p><p>Page 8, paragraph 2:</p><p>“NLR has been considered a prognostic marker in many diseases, such as cancer<sup>20,21</sup> and cardiovascular disease<sup>22</sup>, which may indicate the involvement of complex coordination between different immune response pathways in the disease progression. […] However, the relation between NLR and disease progression rate of ALS is less consistently reported between studies<sup>23,24</sup>, although we did find a higher NLR to be associated with a greater disease progression rate.”</p><disp-quote content-type="editor-comment"><p>(3) The PMIDs 31949271, 34472488, 33974561, 33531377 are missing from the discussion.</p></disp-quote><p>Thank you. We have now added these references in the Discussion.</p><p>Page 8, paragraph 2:</p><p>“NLR has been considered a prognostic marker in many diseases, such as cancer<sup>20,21</sup> and cardiovascular disease<sup>22</sup>, which may indicate the involvement of complex coordination between different immune response pathways in the disease progression. […] However, the relation between NLR and disease progression rate of ALS is less consistently reported between studies<sup>23,24</sup>, although we did find a higher NLR to be associated with a greater disease progression rate.”</p><p>Page 10, paragraph 3:</p><p>“Sex-based immunological difference might exist in response to external and internal antigens, contributing potentially to the variations in the incidence of autoimmune diseases and malignancies as well as the difference in response to vaccines between men and women<sup>44</sup>. […] Although these findings need to be validated, they add on the evidence base to support a potential sex-specific immune response in ALS and ALS as a heterogenous disease.”</p><disp-quote content-type="editor-comment"><p>(4) Additionally, T cells have been investigated in ALS: although a genetic model, the study by Coque et al. is very salient (PMID 30674678), in sporadic ALS patients (PMID 34405141).</p></disp-quote><p>We have now cited the two studies in the Discussion.</p><p>Page 9, paragraph 1:</p><p>“A previous study showed that lower levels of CD56<sup>bright</sup> NK cells in the CSF were associated with faster progression in ALS patients<sup>29</sup>. Additionally, findings from experimental autoimmune encephalomyelitis…”</p><p>In the original manuscript (page 9, paragraph 3), we stated “Previously, CD8<sup>+</sup> T cells have been found to be present in the spinal cord only at the end stage of ALS<sup>5</sup>. However, such cells have been suggested to have a pathogenic potential in multiple sclerosis and to communicate with mononuclear phagocytes<sup>47,48</sup>.”</p><p>We have now revised these sentences as “However, previous animal study showed that activated CD8<sup>+</sup> T cells were present in the CNS of SOD1<sup>G93A</sup> ALS model at the symptomatic stage, and that selective deletion of CD8<sup>+</sup> T cells could increase the survival of motoneurons whereas coculture motoneurons with mutant SOD1-expressing CD8<sup>+</sup> T lymphocytes could selectively kill the motoneurons via Fas and granzyme pathways<sup>37</sup>.”</p></body></sub-article></article>